These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38245436)

  • 1. SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma.
    Jiang A; Liu Y; Zhu B; Fang Y; Qu L; Yang Q; Luo P; Cai C; Wang L
    Clin Genitourin Cancer; 2024 Apr; 22(2):497-513. PubMed ID: 38245436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma.
    Jiang A; Wu X; Wang D; Wang A; Dong K; Liu B; Qu L; Luo P; Wang J; Tong Q; Wang L
    Front Immunol; 2022; 13():935595. PubMed ID: 35935986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma.
    Jiang A; Cai C; Yang Y; Cui Y; Liu W; Pang Q; Wu Z; Liu B; Qu L; Luo P; Wang A; Wang L
    Oxid Med Cell Longev; 2023; 2023():3077091. PubMed ID: 36825082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Senescence gene expression in clear cell renal cell carcinoma: Role of tumor immune microenvironment and senescence-associated survival prediction.
    Wu Y; Li X
    Medicine (Baltimore); 2023 Oct; 102(40):e35222. PubMed ID: 37800815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
    Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
    Front Immunol; 2022; 13():861328. PubMed ID: 35479084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
    Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
    Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Senescence Characteristics Defines a Novel Prognostic Signature to Guide Personalized Treatment for Clear Cell Renal Cell Carcinoma.
    Zhou P; Liu Z; Hu H; Lu Y; Xiao J; Wang Y; Xun Y; Xia Q; Liu C; Hu J; Wang S
    Front Immunol; 2022; 13():901671. PubMed ID: 35720278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma.
    Jiang A; Luo P; Chen M; Fang Y; Liu B; Wu Z; Qu L; Wang A; Wang L; Cai C
    Cell Biosci; 2022 Dec; 12(1):209. PubMed ID: 36581992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.
    Ye S; Tian X; Anwaier A; Wei S; Liu W; Su J; Zhu S; Dai B; Gu J; Qu Y; Xu W; Zhang H; Ye D
    Int J Biol Sci; 2023; 19(14):4552-4570. PubMed ID: 37781030
    [No Abstract]   [Full Text] [Related]  

  • 14. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
    Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma.
    Gong Q; Jiang Y; Xiong J; Liu F; Guan J
    Front Immunol; 2023; 14():1199002. PubMed ID: 37503331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
    Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
    Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of a tryptophan metabolism-related model in the prognostic prediction and immune status for clear cell renal carcinoma.
    Yao Q; Zhang X; Wang Y; Wang C; Wei C; Chen J; Chen D
    Eur J Med Res; 2024 Jan; 29(1):22. PubMed ID: 38183155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: Evidence based on machine learning and experiments.
    Wang T; Jian W; Xue W; Meng Y; Xia Z; Li Q; Xu S; Dong Y; Mao A; Zhang C
    Front Immunol; 2022; 13():1080403. PubMed ID: 36591240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.